ACADIA Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
I'm Charles Duncan. I'm a biotech analyst with Cantor, and it's a pleasure to introduce the next presenting company, ACADIA Pharmaceuticals for the Cantor Global Healthcare Conference in 2023. ACADIA is a company that I have covered for a long time, about a decade or more, and know it quite well. It's an interesting, what I consider, neuro innovator, which has long had a drug for the treatment, the only drug that's approved for the treatment of psychosis associated with Parkinson's disease.
But it has seen a very interesting, I think interesting, evolution in its business with the approval of the first drug ever for the rare developmental neurological disease called the Rett syndrome. And so it's a pleasure to introduce Mark Schneyer, the company's Chief Financial Officer. Mark, thank you for joining.
Thanks for having us.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
